Table 1 Tumour and patient characteristics in Cohort 1 and their association with tumour necrosis.

From: Immunological and prognostic significance of tumour necrosis in colorectal cancer

Characteristic

Total N (%)

Tumour necrosis percentage

<3%

3–9.9%

10–39.9%

≥40%

P value

All cases

 

1100 (100%)

104 (9.5%)

593 (54%)

341 (31%)

62 (5.6%)

 

Sex

Male

557 (51%)

51 (9.2%)

304 (55%)

171 (31%)

31 (5.6%)

0.97

Female

543 (49%)

53 (9.8%)

289 (53%)

170 (31%)

31 (5.7%)

 

Age

<65

290 (26%)

23 (7.9%)

149 (51%)

99 (34%)

19 (6.6%)

0.58

65–75

381 (35%)

35 (9.2%)

215 (56%)

109 (29%)

22 (5.8%)

 

>75

429 (39%)

46 (11%)

229 (53%)

133 (31%)

21 (4.9%)

 

Tumour location

Proximal colon

536 (49%)

63 (12%)

284 (53%)

158 (29%)

31 (5.8%)

0.0001

Distal colon

404 (37%)

24 (5.9%)

205 (51%)

146 (36%)

29 (7.1%)

 

Rectum

160 (15%)

17 (11%)

104 (65%)

37 (23%)

2 (1.3%)

 

T

T1

58 (5.3%)

13 (22%)

34 (59%)

11 (19%)

0 (0%)

<0.0001

T2

169 (15%)

24 (14%)

108 (64%)

37 (22%)

0 (0%)

 

T3

677 (62%)

52 (7.7%)

370 (55%)

221 (33%)

34 (5%)

 

T4

196 (18%)

15 (7.7%)

81 (41%)

72 (37%)

28 (14%)

 

N

N0

626 (57%)

71 (11%)

361 (58%)

171 (27%)

23 (3.7%)

0.0002

N1

275 (25%)

18 (6.5%)

139 (51%)

95 (35%)

23 (8.4%)

 

N2

199 (18%)

15 (7.5%)

93 (47%)

75 (38%)

16 (8.0%)

 

M

M0

947 (86%)

93 (9.8%)

519 (55%)

288 (30%)

47 (5.0%)

0.042

M1

153 (14%)

11 (7.2%)

74 (48%)

53 (35%)

15 (9.8%)

 

Stage

I

184 (17%)

29 (16%)

119 (65%)

36 (20%)

0 (0%)

<0.0001

II

408 (37%)

40 (9.8%)

219 (54%)

126 (31%)

23 (5.6%)

 

III

355 (32%)

24 (6.8%)

181 (51%)

126 (35%)

24 (6.8%)

 

IV

153 (14%)

11 (7.2%)

74 (48%)

53 (35%)

15 (9.8%)

 

WHO grade

Low grade

903 (82%)

78 (8.6%)

501 (55%)

284 (31%)

40 (4.4%)

0.0003

High grade

197 (18%)

26 (13%)

92 (47%)

57 (29%)

22 (11%)

 

Glasgow Microenvironment Score

GMS0

469 (43%)

52 (11%)

288 (61%)

119 (25%)

10 (2.1%)

<0.0001

GMS1

329 (30%)

37 (11%)

163 (50%)

106 (32%)

23 (7.0%)

 

GMS2

302 (27%)

15 (5.0%)

142 (47%)

116 (38%)

29 (9.6%)

 

MMR enzyme status

Proficient

931 (85%)

77 (8.3%)

513 (55%)

293 (31%)

48 (5.2%)

0.004

Deficient

169 (15%)

27 (16%)

80 (49%)

48 (28%)

14 (8.3%)

 

BRAF statusa

Wild-type

916 (83%)

76 (8.3%)

497 (54%)

293 (32%)

50 (5.5%)

0.017

Mutant

182 (17%)

28 (15%)

94 (52%)

48 (26%)

12 (6.6%)

 
  1. aData missing from two patients.